• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.

作者信息

Shah Vallari, Sherborne Amy L, Johnson David C, Ellis Sidra, Price Amy, Chowdhury Farzana, Kendall Jack, Jenner Matthew W, Drayson Mark T, Owen Roger G, Gregory Walter M, Morgan Gareth J, Davies Faith E, Cook Gordon, Cairns David A, Houlston Richard S, Jackson Graham, Kaiser Martin F

机构信息

Division of Molecular Pathology, The Institute of Cancer Research, London, UK.

Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

出版信息

Leukemia. 2020 Nov;34(11):3091-3096. doi: 10.1038/s41375-020-0750-z. Epub 2020 Mar 11.

DOI:10.1038/s41375-020-0750-z
PMID:32157174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7584474/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b32b/7584474/88153d351187/41375_2020_750_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b32b/7584474/88153d351187/41375_2020_750_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b32b/7584474/88153d351187/41375_2020_750_Fig1_HTML.jpg

相似文献

1
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.通过分子谱分析预测超高风险多发性骨髓瘤：对新诊断的适合移植的骨髓瘤XI试验患者的分析
Leukemia. 2020 Nov;34(11):3091-3096. doi: 10.1038/s41375-020-0750-z. Epub 2020 Mar 11.
2
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies.基因表达谱可预测接受新型疗法治疗的新诊断骨髓瘤患者的无复发生存期和总生存期。
Br J Haematol. 2021 Feb;192(4):e115-e120. doi: 10.1111/bjh.17344. Epub 2021 Jan 24.
3
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.回顾性、多国队列 155 例多发性骨髓瘤患者临床试验外治疗的预后基因表达分析。
Int J Lab Hematol. 2022 Feb;44(1):127-134. doi: 10.1111/ijlh.13691. Epub 2021 Aug 26.
4
Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.自体干细胞移植联合治疗对伴有髓外疾病和高危细胞遗传学的新诊断多发性骨髓瘤的疗效改善：来自欧洲血液和骨髓移植学会慢性恶性肿瘤工作组的研究。
Biol Blood Marrow Transplant. 2019 Nov;25(11):2134-2142. doi: 10.1016/j.bbmt.2019.07.004. Epub 2019 Jul 6.
5
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.新诊断骨髓瘤的预后预测：1905 试验患者分子谱的荟萃分析。
Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.
6
Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma.长链非编码RNA NEAT1在多发性骨髓瘤中呈现出与分子特征及临床结局无关的高表达。
Haematologica. 2019 Feb;104(2):e72-e76. doi: 10.3324/haematol.2018.201301. Epub 2018 Sep 13.
7
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.新诊断多发性骨髓瘤中 17p 缺失的基线特征、染色体改变和影响预后的治疗。
Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.
8
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.适合移植的新诊断多发性骨髓瘤患者的总生存：现代诱导方案对结局的比较效果分析。
Blood Cancer J. 2018 Dec 11;8(12):125. doi: 10.1038/s41408-018-0163-7.
9
Prognostic factors in multiple myeloma.多发性骨髓瘤的预后因素
Clin Adv Hematol Oncol. 2005 Mar;3(3):167-8.
10
Deregulated expression of long non-coding RNA UCA1 in multiple myeloma.多发性骨髓瘤中长链非编码 RNA UCA1 的失调表达。
Eur J Haematol. 2017 Sep;99(3):223-233. doi: 10.1111/ejh.12908. Epub 2017 Jun 29.

引用本文的文献

1
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.欧洲血液学年会-欧洲骨髓瘤网络关于多发性骨髓瘤患者诊断、治疗及随访的循证指南
Nat Rev Clin Oncol. 2025 Jul 7. doi: 10.1038/s41571-025-01041-x.
2
Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients.移植后微小残留病阴性在标准风险与高风险及超高风险多发性骨髓瘤患者中的预后价值
Cancers (Basel). 2025 May 4;17(9):1565. doi: 10.3390/cancers17091565.
3
Individualized dynamic risk assessment and treatment selection for multiple myeloma.
多发性骨髓瘤的个体化动态风险评估与治疗选择
Br J Cancer. 2025 Jun;132(10):922-936. doi: 10.1038/s41416-025-02987-6. Epub 2025 Apr 1.
4
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.高危多发性骨髓瘤定义与管理的证据现状
Curr Oncol Rep. 2025 Mar;27(3):258-277. doi: 10.1007/s11912-025-01639-5. Epub 2025 Feb 12.
5
Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram.非移植功能性高危多发性骨髓瘤的早期识别：来自预测列线图的见解
Biomedicines. 2025 Jan 9;13(1):145. doi: 10.3390/biomedicines13010145.
6
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma.结合SKY92基因表达谱分析和荧光原位杂交技术（根据R2国际分期系统）可定义出超高危多发性骨髓瘤。
Hemasphere. 2025 Jan 23;9(1):e70078. doi: 10.1002/hem3.70078. eCollection 2025 Jan.
7
Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.双打击多发性骨髓瘤高危患者自体干细胞移植后 MRD 阴性的真实世界优势和挑战。
BMC Cancer. 2024 Apr 2;24(1):406. doi: 10.1186/s12885-024-12077-0.
8
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.基于 RNA 测序的多发性骨髓瘤一线治疗选择和风险评估。
Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023.
9
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.功能性高危多发性骨髓瘤的定义因素和驱动因素：来自基因组、转录组和免疫分析的见解
Front Oncol. 2023 Oct 2;13:1240966. doi: 10.3389/fonc.2023.1240966. eCollection 2023.
10
Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients.超高风险遗传学对符合移植条件的多发性骨髓瘤患者真实世界结局的影响。
Hemasphere. 2023 Jan 25;7(2):e831. doi: 10.1097/HS9.0000000000000831. eCollection 2023 Feb.